Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.
PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.
The company reported positive Phase III efficacy data on the first-in-class mu-opioid agonist molecule designed to provide pain relief without the euphoria that leads to addiction with standard opioids.